Lynda Schneider is engaged in evaluating new therapies for allergic diseases through clinical trials. Current trials focus on evaluating a multidisciplinary approach to caring for children with atopic dermatitis (AD), exploring the genetics and phenotypes of patients with AD, and oral immunotherapy and epicutaneous immunotherapy for peanut-allergic children.
Throughout the 1990s, Dr. Schneider and colleagues evaluated new treatments for atopic dermatitis, including interferon-gamma, topical tacrolimus, and pimecrolimus. They also studied the use of anti-IgE for food allergy and C1-inhibitor for hereditary angioedema. Other projects have included the use of intravenous immunoglobulin for asthma as well as anti-IgE for asthma.
Her current projects focus on testing ways to reverse food allergies by re-training the immune system to tolerate foods. These trials include, the PRROTECT Study, a trial that explores the use of omalizumab (anti-IgE) in oral immunotherapy for peanut-allergic children and the PEPITES Study, a phase III trial to assess efficacy and safety of peanut epicutaneous immunotherapy in peanut-allergic children. Dr. Schneider also received funding by the National Institute of Health as a site for the Atopic Dermatitis Registry Network: Clinical Studies Consortium.